The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d
With the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow or halt the progressive disease, the community is crying out for new drugs.
Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents h
The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.